medigraphic.com
ISSN 0035-0052 (Print)

2013, Number 6

<< Back Next >>

Rev Mex Pediatr 2013; 80 (6)

Rocky Mountain spotted fever in children: hospital experience

Gómez RN, Álvarez HG, García ZMG, Fonseca CI, Villalobos GL, Cano RMA

Language: Spanish
References: 24
Page: 227-231
PDF size: 126.77 Kb.


ABSTRACT

Objective: Highlight the epidemiological and clinical importance derived from the lab tests state of Rocky Mountain spotted fever (RMSF) in children who were cared for in the children’s hospital in Sonora.
Material and methods: We reviewed the clinical records of 116 children with RMSF admitted in the past 10 years, to report the clinical features and laboratory data as well as the treatment and clinical monitoring in children with a diagnosis of this disease and its lethality.
Results: The fatality rate was 28.3% and by logistic regression analysis there was a significant relationship (p ‹ 0.0001) between the initiation of therapy and survival of children (R2 = 0.49).
Conclusion: The information gathered indicates that Sonora remains an endemic area of RMFS with a high mortality rate and multiple clinical complications.


REFERENCES

  1. Dalton MJ, Clarke MJ, Holman RC, Krebs JW, Fishbein DB, Olson JG et al. National surveillance for Rocky Mountain spotted fever, 1981-92: epidemiologic summary and evaluation of risk factors for fatal outcome. Am J Trop Med Hyg. 1995; 52: 405-13.

  2. Parola P, Raoult P. Ticks and tickborne bacterial diseases in humans: an emerging infectious threat. Clin Infect Dis. 2001; 32: 897-928.

  3. Holman RC, McQuiston JH, Haberling DL, Cheek JE. Increasing incidence of Rocky Mountain spotted fever among the American Indian population in the United States. Am J Trop Med Hyg. 2009; 80(4): 601-5.

  4. World Health Organization. Global surveillance of rickettsial diseases. Bull World Health Organ. 2009; 7: 293-96.

  5. Gómez-Rivera N, Álvarez-Hernández G, García Zarate MG, Fonseca-Chon I, Cano-Rangel MA, Villalobos-García y cols. Fiebre manchada de las “Montañas Rocosas” en niños. Informe de 18 casos. Rev Mex Pediatr. 2009; 76(6); 245-50.

  6. Álvarez-Hernández G. Fiebre manchada de las “Montañas Rocosas”. Bol Clin Hosp Inf Edo Son. 2010; 27(2) 90-92.

  7. Walker DH. Rickettsiae and rickettsial infections: the current state of Knowtedge. Clin Infect Dis. 2007; 45(Suppl 1): 39-44.

  8. Chen LF, Sexton DJ, What’s New in Rocky Mountain spotted fever? Infect Dis Clin N Am. 2008; 22: 415-32.

  9. Holman RC, McQuiston JH, Haberling DL, Cheek JE. Increasing incidence of Rocky Mountain spotted fever among the American Indian population in the United States. Am J Trop Med Hyg. 2009; 80(4): 601-5

  10. Dellinger RP. Surviving Sepsis Campaing. International guidelines for management of severe sepsis and septic shock. Crit Care Med. 2008; 36: 296 -27.

  11. Kilgannon JH, Jones AE, Shapiro NI, Angelos MG, Milcarek B, Hunter K et al. Association between arterial hyperoxia following resuscitation from cardiac arrest and in-hospital mortality. JAMA. 2010; 303: 2165-71.

  12. Openshaw JJ, Swerdlow DL, Krebs JW, Holman RC, Mandel E, Harvey A et al. Rocky Mountain spotted fever in the United States, 2000-2007: interpreting contemporary increases in incidence. Am J Trop Med Hyg. 2010; 83: 174-82.

  13. Walker DH. Rickettsiae and rickettsial infections: the current state of Knowtedge. Clin Infect Dis. 2007; 45: 39-44.

  14. Parola P, Raoult D. Ticks and tickborne bacterial diseases in humans: an emerging infectious threat. Clin Infect Dis. 2001; 32: 897-928.

  15. Thomas EA, John M, Kanish B. Mucocutaneous manifestations of Dengue fever. Indian J Dermatol. 2010; 55: 79-85.

  16. Masters EJ, Olson GS, Weiner, SJ, Paddock CD. Rocky Mountain spotted fever: a clinician’s dilemma. Arch Intern Med. 2003; 163: 769-77.

  17. Purvis JJ, Edwards MS. Doxycycline use for rickettsial disease in pediatric patients. Pediatr Infect Dis J. 2000; 19: 871-874.

  18. Walker DH Raoult D. Rickettsia rickettsii and other spotted fever group Rickettsiae. In: Mandell, Bennett, & Dolin. Principles and Practice of Infectious diseases. 6th edition; 2005; 2287-95.

  19. Paddock CD, Creer PW, Ferebee TL, Singleton J, McKechnie DB, Treadwell TA. Hidden mortality attributable to Rocky Mountain spotted fever: Immunohistochemical detection of fatal serologic unconfirmed disease. J Infect Dis.1999; 179: 1469-1478.

  20. Kaplan JE, Schonberger LB. The sensitivity of various serologic tests in the diagnosis of Rocky Mountain spotted fever. Am J Trop Med Hyg. 1986; 35: 840-42.

  21. Luna GL. Manual of histologic staining methods of the armed forces institute of pathology. Third ed., HT (ASCP); 1960, pp, 237.

  22. Simons, JS, Gentzkow, CJ. Laboratory methods of the United States Army. 5th ed. Philadelphia, Penn., Lea and Febiger; 1944, p.p.572.

  23. Gómez-Rivera N, Molina-Moreno FA, García-Zárate MG, Castillo-Ramos J, García-Hernández RJ, Vazquez-Pizaña E y cols. Procalcitonina semicuntitativa (PCT-Q) como prueba diagnóstica y marcador pronóstico en niños con sepsis bacteriana. Bol Med Hosp Infant Mex. 2006; 63: 8-16.

  24. Janda S, Young A, Fitzgerald JM, Etminan M, Swiston J. The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care. 2010; 25(4): 656.e7-22.




2020     |     www.medigraphic.com